Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by CWA Asset Management Group LLC
CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...
Zacks.com on MSN1d
Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%. On ...
Nasdaq11d
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
That's what recently happened to Vertex Pharmaceuticals (NASDAQ: VRTX), a biotech company. Here is why now is as good a time as any to "buy low" when it comes to this stock. Vertex Pharmaceuticals ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Everence Capital Management Inc.
Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...
Hosted on MSN13d
Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): ‘This Is Hardly Down For The Year. I Think It Can Still Go Lower’
In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the ...
Nordea Investment Management AB Purchases 55,739 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.4% during the fourth quarter, Holdings Channel reports. The ...
Nasdaq5d
Vertex downgraded to Market Perform from Outperform at Raymond James
Raymond James downgraded Vertex (VERX) to Market Perform from Outperform without a price target The firm repositioned several ratings throughout the application software sector at the start of 2025.
Analysts Set Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target at $494.04
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, ...
Nasdaq7d
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
Vertex Pharmaceuticals (VRTX ... At the same time, the Dow lost 0.07%, and the tech-heavy Nasdaq lost 0.9%. Shares of the drugmaker witnessed a loss of 14.25% over the previous month, trailing ...
ETF Daily News8d
Vertex (NASDAQ:VERX) Coverage Initiated by Analysts at DA Davidson
Investment analysts at DA Davidson started coverage on shares of Vertex (NASDAQ:VERX – Get Free Report) in a note issued to investors on Tuesday,Briefing.com Automated Import reports.
Nasdaq12d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...